" class="no-js "lang="en-US"> Patricia Gauthier - Medtech Alert
Wednesday, March 22, 2023
Patricia Gauthier

Patricia Gauthier

About Patricia Gauthier

Since starting in the pharmaceutical industry in 2008, I have had a significant and positive impact on business. Leveraging several years as a lawyer and an MBA, my contributions have included success in negotiations, change management initiatives, leading large teams, and managing P&L ($300M revenue in 2019).

The skills I acquired through the legal field – argumentation, critical thinking, managing complexity and ambiguity – serve me well in business.

Driven and ambitious by nature, I am motivated to produce results, turn challenges into opportunities and seek to make a difference by enabling those I lead to develop their full potential.

Joining Moderna at a critical time, I will take on the challenge and opportunity of building and establishing strong operations for the organization in Canada to deliver on current and future vaccines and therapeutics.

Graduating from HEC Montreal’s MBA program, I joined GSK as part of a leadership development initiative. I repeatedly met business objectives as I began a fast-track path through sales, pricing, marketing, Chief of Staff and leadership roles in market access and government affairs with rapidly expanding responsibilities that culminated in leading the division as Head of Government Affairs and Market Access, Established Brands & Specialty Care.

As Head of the Vaccines Business Unit & Enterprise Digital I drove growth through sales and marketing strategies in the private market, and implement strategic tender approaches in the public market.

You need to know this about me: I positively disrupt status quo to explore what could be, challenge assumptions, design change, and drive results. A few examples follow.
• Transformed threats into opportunities – designed & negotiated innovative and first of its kind product agreements and helped shape policies that favour our corporate goals.
• Led change management initiatives to instill respect for governance and risk management, to develop a performance-based culture as well as cost-saving organizational restructuring.
• Launched new products, grew revenues with pricing strategies, and contributed to GSK’s Leadership Team to drive performance and engagement across the organization.

Related Story

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

August 11 2021

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]